BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 10598045)

  • 1. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
    Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
    Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors and their antitumor effects in model systems.
    Brodie A; Lu Q; Liu Y; Long B
    Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
    Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM
    J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
    Brodie A; Jelovac D; Long BJ
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
    Long BJ; Tilghman SL; Yue W; Thiantanawat A; Grigoryev DN; Brodie AM
    J Steroid Biochem Mol Biol; 1998 Nov; 67(4):293-304. PubMed ID: 9883986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral aromatase model: the effects of letrozole (CGS 20267).
    Brodie A; Lu Q; Yue W; Wang J; Liu Y
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S23-6; discussion S33-7. PubMed ID: 9797014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
    Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
    Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
    Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
    Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
    Yue W; Zhou D; Chen S; Brodie A
    Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.